Liliana Ilut

Liliana Ilut

Auto-generated profile, based on publicly available information

Liliana Ilut

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KPKatarzyna C. Pituch
Katarzyna C. Pituch
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
TXTing Xiao
Ting Xiao
MCMichael Chastkofsky
Michael Chastkofsky
IBIrina Balyasnikova
Irina Balyasnikova
Glioblastoma (GBM) is the most lethal primary brain tumor in adults. No treatment provides durable relief for the vast majority of GBM patients. In this study, we9ve tested a bispecific antibody comprised of single-chain variable fragments (scFvs) against T cell CD3ε and GBM cell interleukin 13 receptor alpha 2 (IL13Rα2). We demonstrate that this bispecific T cell engager (BiTE) (BiTELLON) engages peripheral and tumor-infiltrating lymphocytes harvested from patients9 tumors and, in so doing, exerts anti-GBM activity ex vivo. The interaction of BiTELLON with T cells and IL13Rα2-expressing GBM cells stimulates T cell proliferation and the production of proinflammatory cytokines interferon γ (IFNγ) and tumor necrosis factor α (TNFα). We have modified neural stem cells (NSCs) to produce and secrete the BiTELLON (NSCLLON). When injected intracranially in mice with a brain tumor, NSCLLON show tropism for tumor, secrete BiTELLON, and remain viable for over 7 d. When injected directly into the tumor, NSCLLON provide a significant survival benefit to mice bearing various IL13Rα2+ GBMs. Our results support further investigation and development of this therapeutic for clinical translation. Significance Glioblastoma (GBM) is the most aggressive and lethal brain tumor in adults. The GBM microenvironment is highly immunosuppressive, rendering T cells incapable of recognizing and eliminating malignant cells. We developed bispecific T cell engagers (BiTEs) that successfully engage patients9 T cells to attack and kill GBM expressing interleukin 13 receptor alpha 2 (IL13Rα2). Neural stem cells (NSCs) engineered to secrete BiTE migrate readily within the brain tissue to established tumors and produce BiTE protein within the malignant tissue. Treatment of animals bearing IL13Rα2-expressing patient-derived GBM xenografts with therapeutic NSCs resulted in significant survival benefits in mice. These results show an exciting potential of NSCs as a delivery platform for BiTE therapy to improve outcomes for GBM patients.

27 December 2022 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
SFSarah E. Fenton
Sarah E. Fenton
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
MFMariafausta Fischietti
Mariafausta Fischietti
CJChunni Ji
Chunni Ji
DSDiana Saleiro
Diana Saleiro
Immune checkpoint inhibitors (ICI) have transformed the treatment of melanoma. However, the majority of patients have primary or acquired resistance to ICIs, limiting durable responses and patient survival. IFNγ signaling and the expression of IFNγ-stimulated genes correlate with either response or resistance to ICIs, in a context-dependent manner. While IFNγ-inducible immunostimulatory genes are required for response to ICIs, chronic IFNγ signaling induces the expression of immunosuppressive genes, promoting resistance to these therapies. Here, we show that high levels of Unc-51 like kinase 1 (ULK1) correlate with poor survival in patients with melanoma and overexpression of ULK1 in melanoma cells enhances IFNγ-induced expression of immunosuppressive genes, with minimal effects on the expression of immunostimulatory genes. In contrast, genetic or pharmacologic inhibition of ULK1 reduces expression of IFNγ-induced immunosuppressive genes. ULK1 binds IRF1 in the nuclear compartment of melanoma cells, controlling its binding to the programmed death-ligand 1 promoter region. In addition, pharmacologic inhibition of ULK1 in combination with anti-programmed cell death protein 1 therapy further reduces melanoma tumor growth in vivo. Our data suggest that targeting ULK1 represses IFNγ-dependent immunosuppression. These findings support the combination of ULK1 drug-targeted inhibition with ICIs for the treatment of patients with melanoma to improve response rates and patient outcomes. Implications: This study identifies ULK1, activated downstream of IFNγ signaling, as a druggable target to overcome resistance mechanisms to ICI therapy in metastatic melanoma.

3 April 2023
Verified
Other
Open access
SFSarah E. Fenton
Sarah E. Fenton
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
MFMariafausta Fischietti
Mariafausta Fischietti
CJChunni Ji
Chunni Ji
DSDiana Saleiro
Diana Saleiro
List of the putative ULK1 interactor proteins identified by mass spectrometry analysis in A375 cells

3 April 2023
Verified
Other
Open access
SFSarah E. Fenton
Sarah E. Fenton
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
MFMariafausta Fischietti
Mariafausta Fischietti
CJChunni Ji
Chunni Ji
DSDiana Saleiro
Diana Saleiro
Immune checkpoint inhibitors (ICI) have transformed the treatment of melanoma. However, the majority of patients have primary or acquired resistance to ICIs, limiting durable responses and patient survival. IFNγ signaling and the expression of IFNγ-stimulated genes correlate with either response or resistance to ICIs, in a context-dependent manner. While IFNγ-inducible immunostimulatory genes are required for response to ICIs, chronic IFNγ signaling induces the expression of immunosuppressive genes, promoting resistance to these therapies. Here, we show that high levels of Unc-51 like kinase 1 (ULK1) correlate with poor survival in patients with melanoma and overexpression of ULK1 in melanoma cells enhances IFNγ-induced expression of immunosuppressive genes, with minimal effects on the expression of immunostimulatory genes. In contrast, genetic or pharmacologic inhibition of ULK1 reduces expression of IFNγ-induced immunosuppressive genes. ULK1 binds IRF1 in the nuclear compartment of melanoma cells, controlling its binding to the programmed death-ligand 1 promoter region. In addition, pharmacologic inhibition of ULK1 in combination with anti-programmed cell death protein 1 therapy further reduces melanoma tumor growth in vivo. Our data suggest that targeting ULK1 represses IFNγ-dependent immunosuppression. These findings support the combination of ULK1 drug-targeted inhibition with ICIs for the treatment of patients with melanoma to improve response rates and patient outcomes.Implications:This study identifies ULK1, activated downstream of IFNγ signaling, as a druggable target to overcome resistance mechanisms to ICI therapy in metastatic melanoma.

3 April 2023
Verified
Other
Open access
SFSarah E. Fenton
Sarah E. Fenton
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
MFMariafausta Fischietti
Mariafausta Fischietti
CJChunni Ji
Chunni Ji
DSDiana Saleiro
Diana Saleiro
S1. Overexpression of ULK1 in melanoma cells has minor effects on transcription of IFNγ-induced immunostimulatory genes.S2. Effects of gene targeted inhibition of ULK1 in transcription of IFNγ-induced immunostimulatory genes in melanoma cells.S3. Effects of drug-targeted inhibition of ULK1 in transcription of IFNγ-induced immunostimulatory genes in melanoma cells.S4. Effects of siRNA-mediated knockdown of ULK1 on IFNγ-inducedSTAT1 phosphorylation.S5. Identification of putative cytoplasmic and nuclear ULK1 binding partners in melanoma cells upon IFNγ stimulation by mass spectrometry analysis.S6. Pharmacological inhibition of ULK1 enhances the anti-tumor effects of anti-PD-1 therapy in YUMMER1.7 mouse melanoma in vivo model.S7. Tumor infiltrating CD8+ T cells and TAMCs in vehicle-isotype-treated mice.S8. Tumor infiltrating CD8+ T cells and TAMCs in ULK inhibitor-treated mice.S9. Tumor infiltrating CD8+ T cells and TAMCs in anti-PD-1-treated mice.S10. Tumor infiltrating CD8+ T cells and TAMCs in ULKi plus anti-PD-1-treated mice.S11. Tumor infiltrating CD4+ T cells and Tregs in vehicle-isotype-treated mice.S12. Tumor infiltrating CD4+ T cells and Tregs in ULK inhibitor-treated mice.S13. Tumor infiltrating CD4+ T cells and Tregs in anti-PD-1treated mice.S14. Tumor infiltrating CD4+ T cells and Tregs in ULKi plus anti-PD-1-treated mice.S15. Tumor infiltrating CD8+ T cells and TAMCs in control, ULKi and/or anti-PD-1-treated mice.S16. Tumor infiltrating CD4+ T cells and Tregs in control, ULKi and/or anti-PD-1-treated mice.S17. Gating strategy for flow cytometric immunophenotyping of mouse melanoma tumors.

3 April 2023
Verified
Other
Open access
SFSarah E. Fenton
Sarah E. Fenton
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
MFMariafausta Fischietti
Mariafausta Fischietti
CJChunni Ji
Chunni Ji
DSDiana Saleiro
Diana Saleiro
List of the putative ULK1 interactor proteins identified by mass spectrometry analysis in A375 cells